Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - terbutaline sulfate, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - indications ast at 24 june 2004: for relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm. bricanyl injection: bricanyl injection solution is recommended for acute use only.

Evrópusambandið - enska - EMA (European Medicines Agency)

astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - olaparib, quantity: 50 mg - capsule - excipient ingredients: gellan gum; hypromellose; titanium dioxide; potassium acetate; lauroyl macrogolglycerides; iron oxide black; shellac - olaparib is indicated as monotherapy for the maintenance treatment of patients with platinum-sensitive relapsed brca-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. prior treatment must have included at least 2 courses of platinum-based regimens.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 10 mg - tablet, modified release - excipient ingredients: sodium stearylfumarate; carnauba wax; hypromellose; aluminium sodium silicate; iron oxide red; titanium dioxide; hyprolose; lactose; iron oxide yellow; peg-40 hydrogenated castor oil; microcrystalline cellulose; macrogol 6000; propyl gallate - hypertension.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 5 mg - tablet, modified release - excipient ingredients: aluminium sodium silicate; sodium stearylfumarate; propyl gallate; lactose; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; microcrystalline cellulose; iron oxide red; carnauba wax; peg-40 hydrogenated castor oil; macrogol 6000 - hypertension.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 2.5 mg - tablet, modified release - excipient ingredients: hypromellose; iron oxide yellow; lactose; aluminium sodium silicate; macrogol 6000; propyl gallate; titanium dioxide; microcrystalline cellulose; sodium stearylfumarate; hyprolose; peg-40 hydrogenated castor oil; carnauba wax - hypertension.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - formoterol fumarate dihydrate, quantity: 4.5 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - long-term treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise induced asthma) in adults and children aged 12 years and over and who are receiving inhaled or oral corticosteroids and who require bronchodilator therapy.,oxis turbuhaler can be used on demand (prn) in asthmatics over the age of 18 years who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed alone by occasional use of short acting inhaled beta-2 agonists.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - formoterol fumarate dihydrate, quantity: 9 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - long-term treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise induced asthma) in adults and children aged 12 years and over and who are receiving inhaled or oral corticosteroids and who require bronchodilator therapy.,oxis turbuhaler can be used on demand (prn) in asthmatics over the age of 18 years who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed alone by occasional use of short acting inhaled beta-2 agonists.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; hypromellose; macrogol 300; lactose monohydrate; povidone; magnesium stearate; titanium dioxide; purified water; industrial methylated spirit - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonist.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 10 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; titanium dioxide; peg-40 hydrogenated castor oil; propyl gallate; hyprolose; iron oxide red; hypromellose; macrogol 6000; iron oxide yellow; sodium stearylfumarate; aluminium sodium silicate; lactose; carnauba wax - hypertension.